Does Fermatron plus improve pain and functioning in patients with knee OA compared to placebo?

Does Fermatron plus improve pain and functioning in patients with knee OA compared to placebo? - Fermathron plus versus placebo

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON31817

Enrollment

200

Registered

2009-02-26

Start date

2009-06-30

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

degenerative joint disease Osteoarthritis

Interventions

Included patients are randomised to either the treatment group (3 injections with Fermathron plus) or to the placebo group (3 injections with saline)

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Mild osteoarthritis of the knee, Kellgren-Lawrence grade I-III

Exclusion criteria

Exclusion criteria: Bilateral osteoarthritis of the knee Pregnancy Lactation Infection of the knee evidence of skin disease

Design outcomes

Secondary

Measure	Time frame
1. Patient satisfaction with the applied treatment 2. Safety of the applied treatment. 3. Range of motion in the affected knee	—

Primary

Measure	Time frame
1. Pain in the affected knee 2. Restricions in daily activities due to the affected knee	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)